Wednesday, June 25, 2014

Celebrex Ad




Celebrex Ad
Celecoxib (Brand name Celebrex)
History
Two lawsuits arose over discovery of celecoxib. Daniel L. Simmons of Brigham Young University discovered the COX-2 enzyme,[30] and BYU entered into a collaboration with Monsanto to develop drugs to inhibit it. BYU ended up suing Pfizer for breach of contract.[31] A settlement was reached in April 2012 in which Pfizer agreed to pay $450 million.[32][33] Other important discoveries in COX-2 were made at University of Rochester, which patented the discoveries.[34] When the patent issued, the university sued Searle (later Pfizer) in a case called, University of Rochester v. G.D. Searle & Co., 358 F.3d 916 (Fed. Cir. 2004). The court ruled in favor of Searle in 2004, holding in essence that the university had claimed a method requiring, yet provided no written description of, a compound that could inhibit COX-2 and therefore the patent was invalid.[35][36]

Celecoxib was discovered and[37] developed by G. D. Searle & Company and was approved by the FDA on December 31, 1998.[38] It was co-promoted by Monsanto Company (parent company of Searle) and Pfizer under the brand name Celebrex. Monsanto merged with Pharmacia, from which the Medical Research Division was acquired by Pfizer, giving Pfizer ownership of Celebrex. The drug was at the core of a major patent dispute that was resolved in Searle's favor (later Pfizer) in 2004.[35][36] In University of Rochester v. G.D. Searle & Co., 358 F.3d 916 (Fed. Cir. 2004), the University of Rochester claimed that United States Pat. No. 6,048,850 (which claimed a method of inhibiting COX-2 in humans using a compound, without actually disclosing what that compound might be) covered drugs such as celecoxib. The court ruled in favor of Searle, holding in essence that the University had claimed a method requiring, yet provided no written description of, a compound that could inhibit COX-2 and therefore the patent was invalid.

After the withdrawal of rofecoxib (Vioxx) from the market in September 2004, Celebrex enjoyed a robust increase in sales. However, the results of the APC trial in December of that year raised concerns that Celebrex might carry risks similar to those of Vioxx, and Pfizer announced a moratorium on direct-to-consumer advertising of Celebrex soon afterwards. After a significant drop, sales of Celebrex have recovered, and reached $2 billion in 2006.[15] Pfizer resumed advertising Celebrex in magazines in 2006,[39] and resumed television advertising in April 2007 with an unorthodox, 2 1⁄2-minute advertisement which extensively discussed the adverse effects of Celebrex in comparison with other anti-inflammatory drugs. The ad drew criticism from the consumer advocacy group Public Citizen, which called the ad's comparisons misleading.[40] Pfizer responded to Public Citizen's concerns with assurances that they are truthfully advertising the risk and benefits of Celebrex as set forth by the FDA.[40]

In late 2007, Pfizer released another US television ad for Celebrex, which also discussed celecoxib's adverse effects in comparison with those of other anti-inflammatory drugs.

Society and culture
Fabricated efficacy studies
On March 11, 2009, Scott S. Reuben, former chief of acute pain at Baystate Medical Center, Springfield, Massachusetts, revealed that the data for 21 studies he had authored for the efficacy of the drug (along with others such as Vioxx) had been fabricated. The analgesic effects of the drugs had been exaggerated. Reuben was also a former paid spokesperson for Pfizer. None of the retracted studies were submitted to either the US Food and Drug Administration or the European Union's regulatory agencies prior to the drug's approval. Pfizer issued a public statement declaring, "It is very disappointing to learn about Dr. Scott Reuben's alleged actions. When we decided to support Dr. Reuben's research, he worked for a credible academic medical center and appeared to be a reputable investigator.

G.D. Searle & Co
Monsanto Company acquired the G.D. Searle & Co.

Note: Michael R. Taylor was the VP for public policy at the Monsanto Company, and is the deputy commissioner for foods for the U.S. Food and Drug Administration (FDA).
Mark B. McClellan was the commissioner for the U.S. Food and Drug Administration (FDA), and a senior fellow at the Brookings Institution (think tank).
Foundation to Promote Open Society was a funder for the Brookings Institution (think tank), the Carnegie Endowment for International Peace (think tank), and the Aspen Institute (think tank).
George Soros was the chairman for the Foundation to Promote Open Society.
Klaus Kleinfeld is a trustee at the Brookings Institution (think tank), a director at Bayer AG, and a 2008 Bilderberg conference participant (think tank).
Bayer AG
The Bayer company then became part of IG Farben, a German chemical company conglomerate. During World War II, the IG Farben used slave labor in factories attached to large slave labor camps, notably the sub-camps of the Mauthausen-Gusen concentration camp.[3] IG Farben owned 42.5% of the company that manufactured Zyklon B,[4] a chemical used in the gas chambers of Auschwitz and other extermination camps. After World War II, the Allies broke up IG Farben and Bayer reappeared as an individual business. The Bayer executive Fritz ter Meer, sentenced to seven years in prison during the IG Farben Military Tribunal at Nuremberg, was made head of the supervisory board of Bayer in 1956, after his release.
Bayer Corporation is the North American subsidiary for Bayer AG.
Mayer Brown was the lobby firm for the Bayer Corporation, and Pfizer Inc.
Robert A. Helman is a partner at Mayer Brown, a member of the Commercial Club of Chicago, and was an honorary trustee at the Brookings Institution (think tank).
William M. Daley 
Professional career 
Daley returned to the practice of law, as a partner with the firm Mayer Brown (then Mayer, Brown & Platt) from 1993 to 1997.
William M. Daley was a partner at Mayer Brown, the chief of staff for the Barack Obama administration, and is a member of the Commercial Club of Chicago.
Edward M. Liddy is a member of the Commercial Club of Chicago, and was the CFO for G.D. Searle & Co.
Monsanto Company acquired the G.D. Searle & Co.
R. Eden Martin is the president of the Commercial Club of Chicago, and counsel at Sidley Austin LLP
Newton N. Minow is a member of the Commercial Club of Chicago, and a senior counsel at Sidley Austin LLP.
Michelle Obama was a lawyer at Sidley Austin LLP.
Barack Obama was an intern at Sidley Austin LLP.
Sidley Austin LLP is the lobby firm for Bayer HealthCare, and the Pharmaceutical Research and Manufacturers of America, was the lobby firm for Pfizer Inc., and the Monsanto Company.
Akin, Gump, Strauss, Hauer & Feld, LLP is the lobby firm for Monsanto Company, Pfizer Inc., and the Pharmaceutical Research and Manufacturers of America.
Vernon E. Jordan Jr. is a senior counsel for Akin, Gump, Strauss, Hauer & Feld, LLP, Valerie B. Jarrett’s great uncle, an honorary trustee at the Brookings Institution (think tank), a director at the American Friends of Bilderberg (think tank), and a 2008 Bilderberg conference participant (think tank).
Valerie B. Jarrett is Vernon E. Jordan Jr’s great niece, the senior adviser for the Barack Obama administration, and a member of the Commercial Club of Chicago.
Edward M. Liddy is a member of the Commercial Club of Chicago, and was the CFO for G.D. Searle & Co.
Commercial Club of Chicago, Members Directory A-Z (Past Research)
Tuesday, December 17, 2013
Cyrus F. Freidheim Jr. is a member of the Commercial Club of Chicago, and an honorary trustee at the Brookings Institution (think tank).
Constance J. Horner was a guest scholar at the Brookings Institution (think tank), and is a director at Pfizer Inc.
Amy W. Schulman is a trustee at the Brookings Institution (think tank), and the EVP & general counsel for Pfizer Inc.
Suzanne Nora Johnson is a trustee at the Brookings Institution (think tank), a director at Pfizer Inc., and a trustee at the Carnegie Institution for Science.
Jessica Tuchman Mathews was an honorary trustee at the Brookings Institution (think tank), is the president of the Carnegie Endowment for International Peace (think tank), a director at the American Friends of Bilderberg (think tank), and a 2008 Bilderberg conference participant (think tank).
Ed Griffin’s interview with Norman Dodd in 1982
(The investigation into the Carnegie Endowment for International Peace uncovered the plans for population control by involving the United States in war)
Andrew Carnegie was the founder of the Carnegie Endowment for International Peace (think tank), and the founder of the Carnegie Institution for Science.
David F. Swensen is a senior trustee at the Carnegie Institution for Science, and was a trustee at the Brookings Institution (think tank).
William T. Coleman Jr. is a senior trustee at the Carnegie Institution for Science, an honorary trustee at the Brookings Institution (think tank), and was a lifetime trustee at the Aspen Institute (think tank).
Javier Solana is a trustee at the Aspen Institute (think tank), and was the high representative for common foreign & security policy for the European Union.
John P. Mascotte was a lifetime trustee at the Aspen Institute (think tank), and a director at the Pfizer Inc.
James S. Crown is a trustee at the Aspen Institute (think tank), and a member of the Commercial Club of Chicago.
Lester Crown was a lifetime trustee at the Aspen Institute (think tank), and is a member of the Commercial Club of Chicago.
Edward M. Liddy is a member of the Commercial Club of Chicago, and was the CFO for G.D. Searle & Co.
Monsanto Company acquired the G.D. Searle & Co.












No comments: